Dr William Daniel Porter, MD, MPH | |
1700 University Dr E, College Station, TX 77840-2661 | |
(979) 691-3300 | |
(979) 691-3527 |
Full Name | Dr William Daniel Porter |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 1700 University Dr E, College Station, Texas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356364921 | NPI | - | NPPES |
Entity Name | Scott & White Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
Dr John Griffiths, a Cancer Research UK-funded scientist, has received the 2010 European Magnetic Resonance Award for Basic Sciences.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.
Senior citizens and combat soldiers don't usually have much in common-unless the topic is bone injuries. Among both groups, mending serious skeletal injuries-whether caused by a blast or a common fall-is a costly, complicated challenge.
Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have developed a novel technique to promote tissue repair in damaged muscles.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr William Daniel Porter, MD, MPH Po Box 844658, Dallas, TX 75284-4658 Ph: (800) 994-0371 | Dr William Daniel Porter, MD, MPH 1700 University Dr E, College Station, TX 77840-2661 Ph: (979) 691-3300 |
News Archive
Dr John Griffiths, a Cancer Research UK-funded scientist, has received the 2010 European Magnetic Resonance Award for Basic Sciences.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma.
Senior citizens and combat soldiers don't usually have much in common-unless the topic is bone injuries. Among both groups, mending serious skeletal injuries-whether caused by a blast or a common fall-is a costly, complicated challenge.
Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have developed a novel technique to promote tissue repair in damaged muscles.
› Verified 5 days ago
Dr. Barbara Tyler, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: Beutel Health Ctr, College Station, TX 77843 Phone: 979-458-8374 |